At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TECX Tectonic Therapeutic, Inc.
Market Closed 10-09 16:00:00 EDT
23.33
+0.58
+2.55%
盘后23.33
+0.000.00%
19:30 EDT
High23.61Low22.74Vol110.71K
Open22.74D1 Closing22.75Amplitude3.82%
Mkt Cap456.09MTradable Cap284.61MTotal Shares19.55M
T/O2.58MT/O Rate0.91%Tradable Shares12.20M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

UBS Initiates a Hold Rating on Tectonic Therapeutic (TECX)
TIPRANKS  ·  06:57
UBS Initiates a Hold Rating on Tectonic Therapeutic (TECX)
Tectonic Therapeutic CSO Peter McNamara Disposes of 980 Common Shares Worth $22,812.48
Reuters  ·  10-03
Tectonic Therapeutic CSO Peter McNamara Disposes of 980 Common Shares Worth $22,812.48
Tectonic Therapeutic Currently Down 13 Days Straight, on Pace for Record Losing Streak
Dow Jones  ·  10-02
Tectonic Therapeutic Currently Down 13 Days Straight, on Pace for Record Losing Streak
Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Tectonic Therapeutic (TECX)
TIPRANKS  ·  09-30
Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Tectonic Therapeutic (TECX)
FDA Grants Tectonic Tx2100 Fast Track Status for HHT
Reuters  ·  09-30
FDA Grants Tectonic Tx2100 Fast Track Status for HHT
Tectonic Therapeutic on Track for Longest Losing Streak Since November 2021
Dow Jones  ·  09-30
Tectonic Therapeutic on Track for Longest Losing Streak Since November 2021
Analyst Maintains Buy on TECX as TX2100 Advaces on Compressed Path to Proof-of-Concept; $88 Price Target Unchanged
TIPRANKS  ·  09-29
Analyst Maintains Buy on TECX as TX2100 Advaces on Compressed Path to Proof-of-Concept; $88 Price Target Unchanged
Tectonic Therapeutic Reports Favorable Phase 1a Results for Tx2100 in HHT Program
Reuters  ·  09-29
Tectonic Therapeutic Reports Favorable Phase 1a Results for Tx2100 in HHT Program
Tectonic Therapeutic, - Tx2100 Trial Reported Only Mild or Moderate Transient Adverse Events; no Deaths or Serious Events
THOMSON REUTERS  ·  09-29
Tectonic Therapeutic, - Tx2100 Trial Reported Only Mild or Moderate Transient Adverse Events; no Deaths or Serious Events
Tectonic Therapeutic, - FDA Grants Fast Track Designation for Tx2100 in Hht and Clears Ind for Phase 1B Trial
THOMSON REUTERS  ·  09-29
Tectonic Therapeutic, - FDA Grants Fast Track Designation for Tx2100 in Hht and Clears Ind for Phase 1B Trial
Tectonic Therapeutic, - Tx2100 Phase 1a Trial Shows Single Ascending Doses Generally Safe and Well-Tolerated
THOMSON REUTERS  ·  09-29
Tectonic Therapeutic, - Tx2100 Phase 1a Trial Shows Single Ascending Doses Generally Safe and Well-Tolerated
Tectonic Therapeutic, - Plans to Initiate Tx2100 Phase 1B Trial by Year-End 2026 and Phase 2 in Early 2027
THOMSON REUTERS  ·  09-29
Tectonic Therapeutic, - Plans to Initiate Tx2100 Phase 1B Trial by Year-End 2026 and Phase 2 in Early 2027
Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and Pk Results for Tx2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (Hht)
THOMSON REUTERS  ·  09-29
Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and Pk Results for Tx2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (Hht)
Tectonic Therapeutic, - Pk Results Support Once Weekly and Every Other Week Subcutaneous Dosing Regimens
THOMSON REUTERS  ·  09-29
Tectonic Therapeutic, - Pk Results Support Once Weekly and Every Other Week Subcutaneous Dosing Regimens
Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference
GlobeNewswire  ·  09-03
Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference
Tectonic Therapeutic (TECX) Gets a Buy from Oppenheimer
TIPRANKS  ·  09-01
Tectonic Therapeutic (TECX) Gets a Buy from Oppenheimer
Tectonic Therapeutic (TECX) Receives a Buy from Piper Sandler
TIPRANKS  ·  08-31
Tectonic Therapeutic (TECX) Receives a Buy from Piper Sandler
Tectonic Therapeutic CSO Peter McNamara Disposes of USD 1,570.36 in Common Shares
Reuters  ·  08-27
Tectonic Therapeutic CSO Peter McNamara Disposes of USD 1,570.36 in Common Shares
Tectonic Therapeutic CSO Peter McNamara Reports TECX Common Share Disposal Worth $1,505 on Aug. 12
Reuters  ·  08-15
Tectonic Therapeutic CSO Peter McNamara Reports TECX Common Share Disposal Worth $1,505 on Aug. 12
Truist Financial Sticks to Its Buy Rating for Tectonic Therapeutic (TECX)
TIPRANKS  ·  08-10
Truist Financial Sticks to Its Buy Rating for Tectonic Therapeutic (TECX)

Introduction

Company Name.
Tectonic Therapeutic, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
Issue price:
--